
SplitNov 20, 2026, 04:36 PM
Theriva Biologics Announces 1-for-30 Reverse Stock Split
AI Summary
Theriva Biologics, Inc. announced a 1-for-30 reverse stock split of its common stock, effective December 1, 2026. This action is intended to ensure compliance with the minimum per share price requirements of the NYSE American. The company's stock will begin trading on a split-adjusted basis on December 2, 2026. Fractional shares will be rounded up to the nearest whole share, and adjustments will be made to outstanding warrants and stock options.
Key Highlights
- Theriva Biologics implements a 1-for-30 reverse stock split.
- Effective date: December 1, 2026.
- Trading on split-adjusted basis begins: December 2, 2026.
- Outstanding shares to reduce from 45,892,668 to approx. 1,529,756.
- Authorized shares to reduce from 350,000,000 to 11,666,666.
- Purpose: Meet NYSE American minimum per share price requirements.
- Fractional shares will be rounded up to the next whole share.
Price Impact
More from TOVX